Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 602,389
  • Shares Outstanding, K 236,231
  • Annual Sales, $ 160,180 K
  • Annual Income, $ -69,410 K
  • EBIT $ -50 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.94
  • Price/Sales 3.54
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.53% ( +7.96%)
  • Historical Volatility 101.69%
  • IV Percentile 50%
  • IV Rank 20.74%
  • IV High 308.17% on 03/19/24
  • IV Low 29.81% on 08/21/24
  • Put/Call Vol Ratio 0.49
  • Today's Volume 4,794
  • Volume Avg (30-Day) 1,308
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 34,306
  • Open Int (30-Day) 29,769

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +67.21%
on 03/13/25
2.58 -1.16%
on 03/18/25
+0.48 (+23.19%)
since 02/18/25
3-Month
1.52 +67.21%
on 03/13/25
2.58 -1.16%
on 03/18/25
+0.79 (+44.89%)
since 12/18/24
52-Week
0.80 +218.75%
on 06/26/24
2.58 -1.16%
on 03/18/25
+0.66 (+34.92%)
since 03/18/24

Most Recent Stories

More News
Akebia Therapeutics: Q4 Earnings Snapshot

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 2.55 (+6.25%)
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

AKBA : 2.55 (+6.25%)
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

AKBA : 2.55 (+6.25%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AKBA : 2.55 (+6.25%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AKBA : 2.55 (+6.25%)
New Strong Sell Stocks for January 3rd

Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today:Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has...

KOF : 89.58 (+0.54%)
GES : 12.19 (-3.41%)
AKBA : 2.55 (+6.25%)
New Strong Sell Stocks for December 5th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has...

KOF : 89.58 (+0.54%)
AKBA : 2.55 (+6.25%)
XRAY : 15.74 (+0.96%)
New Strong Sell Stocks for November 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. ATI is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised...

ALTG : 5.16 (-2.64%)
ATI : 50.67 (-1.38%)
AKBA : 2.55 (+6.25%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 2.55 (+6.25%)
Talis: Q2 Earnings Snapshot

Talis: Q2 Earnings Snapshot

AKBA : 2.55 (+6.25%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 2.90
2nd Resistance Point 2.74
1st Resistance Point 2.64
Last Price 2.55
1st Support Level 2.39
2nd Support Level 2.23
3rd Support Level 2.14

See More

52-Week High 2.58
Last Price 2.55
Fibonacci 61.8% 1.90
Fibonacci 50% 1.69
Fibonacci 38.2% 1.48
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar